Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002), our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX™ exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most.
The Medical Science Liaison (MSL) Director is a field-based scientific leader responsible for delivering Capricor's scientific engagement strategy across an assigned territory of national and regional KOLs treating Duchenne muscular dystrophy (DMD) and DMD cardiomyopathy. The role focuses on scientific exchange with thought leaders, treatment centers, and academic institutions in neuromuscular disease, cardiology, and pediatric specialty care; identification of clinical and research opportunities; and translation of field insights into Capricor's medical strategy for Deramiocel. This individual partners closely with the Medical Director, VP Medical Affairs, HEOR / RWE, Pharmacovigilance, Clinical Development, and the broader U.S. MSL team.